L E Kristensen

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
    Lars Erik Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Arthritis Rheum 54:600-6. 2006
  2. ncbi Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
    Lars Erik Kristensen
    Department of Rheumatology, Lund University Hospital, Kioskgatan 3, SE 221 85 Lund, Sweden
    Arthritis Res Ther 8:R174. 2006
  3. ncbi Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 48:243-5. 2009
  4. ncbi Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:495-9. 2008
  5. ncbi Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
    J A Karlsson
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:507-13. 2008
  6. ncbi The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 36:411-7. 2007
  7. ncbi Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
    A Gulfe
    Department of Rheumatology, Lund University Hospital, Sweden
    Ann Rheum Dis 69:352-7. 2010
  8. ncbi Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    South Sweden Musculoskeletal Research Centre, Lund University Hospital, Lund University, Sweden
    Arthritis Care Res (Hoboken) 62:1362-9. 2010
  9. ncbi Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 67:364-9. 2008
  10. ncbi The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials
    L E Kristensen
    Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Sweden
    Scand J Rheumatol 40:1-7. 2011

Collaborators

Detail Information

Publications11

  1. ncbi The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
    Lars Erik Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Arthritis Rheum 54:600-6. 2006
    ..To describe the use of the LUNDEX, a new index for comparing the long-term efficacy and tolerability of biologic therapies in rheumatoid arthritis (RA) patients treated in clinical practice...
  2. ncbi Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
    Lars Erik Kristensen
    Department of Rheumatology, Lund University Hospital, Kioskgatan 3, SE 221 85 Lund, Sweden
    Arthritis Res Ther 8:R174. 2006
    ..Concomitant MTX is associated with improved treatment continuation of biologics when compared with both TNF blockers as monotherapy and TNF blockers combined with other DMARDs...
  3. ncbi Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 48:243-5. 2009
    ..To study frequency of dose escalation in infliximab-treated patients and to identify possible predictors thereof...
  4. ncbi Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:495-9. 2008
    ..To identify factors predicting response to first TNF blocking treatment course in patients with established RA with a special focus on gender differences...
  5. ncbi Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
    J A Karlsson
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Rheumatology (Oxford) 47:507-13. 2008
    ..To study treatment response rates of RA patients undergoing second- and third-line anti-TNF therapy and to identify baseline predictors of response to second-line treatment...
  6. ncbi The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 36:411-7. 2007
    ..To compare the efficacy of adalimumab, etanercept, and infliximab in patients with established rheumatoid arthritis (RA) taking concomitant methotrexate (MTX) by calculating the number needed to treat (NNT) using three different methods...
  7. ncbi Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden
    A Gulfe
    Department of Rheumatology, Lund University Hospital, Sweden
    Ann Rheum Dis 69:352-7. 2010
    ..Industry-independent health economic studies should complement studies sponsored by industry...
  8. ncbi Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register
    L E Kristensen
    South Sweden Musculoskeletal Research Centre, Lund University Hospital, Lund University, Sweden
    Arthritis Care Res (Hoboken) 62:1362-9. 2010
    ..To examine clinical characteristics as possible predictors of long-term treatment continuation with adalimumab, etanercept, and infliximab in ankylosing spondylitis (AS) patients who had never taken biologics treated in clinical practice...
  9. ncbi Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
    L E Kristensen
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    Ann Rheum Dis 67:364-9. 2008
    ....
  10. ncbi The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials
    L E Kristensen
    Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Sweden
    Scand J Rheumatol 40:1-7. 2011
    ....
  11. ncbi Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden
    Anders Gülfe
    Department of Rheumatology, Lund University Hospital, SE 221 85 Lund, Sweden
    J Rheumatol 36:517-21. 2009
    ..To investigate if treatment response predicts continuation of anti-tumor necrosis factor (TNF) treatment in patients with rheumatoid arthritis (RA)...